Quick Answer
Enveric Biosciences, Inc. reported R&D Expense of $2.78 million for fiscal year 2025.
Enveric Biosciences, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $2.78M | -2.1% |
| 2024 | $2.84M | -60.8% |
| 2023 | $7.25M | -9.7% |
| 2022 | $8.03M | +67.6% |
| 2021 | $4.79M | +2650.9% |
| 2020 | $174.1K | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $402.4K | -49.9% | -68.1% |
| June 30, 2025 | $1.26M | +123.0% | +68.8% |
| March 31, 2025 | $746.4K | +47.5% | -7.0% |
| September 30, 2024 | $802.7K | -37.4% | +42.1% |
| June 30, 2024 | $565.0K | -76.4% | +11.6% |
| March 31, 2024 | $506.2K | -72.3% | -60.5% |
| September 30, 2023 | $1.28M | -37.7% | -46.5% |
| June 30, 2023 | $2.40M | +13.0% | +31.2% |
- Enveric Biosciences, Inc. showed a decrease of -2.1% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, Enveric Biosciences, Inc.’s r&d expense has grown by 1497.5% (from $174.1 thousand to $2.78 million).
- The most recent figure is from Enveric Biosciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: